Melflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan flufenamide)…
News
Oncopeptides’ Accelerated Approval Filing for Melflufen in US Unimpeded by COVID-19
Despite some interruptions to melflufen‘s (melphalan flufenamide) clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in…
Genetic Test May Help Identify Ultra High-risk Multiple Myeloma
A novel genetic test could help identify people with multiple myeloma who are at highest risk of aggressive disease and unlikely to respond to standard…
Ninlaro Combo Fails to Extend New Myeloma Patients’ Survival Without Disease Worsening
A combination of Ninlaro (ixazomib), Revlimid (lenalidomide), and dexamethasone failed to significantly extend the time to disease progression or death in people…
FDA Names Arcellx’s Cell Therapy CART-ddBCMA Orphan Drug for Multiple Myeloma
Arcellx’s CART-ddBCMA — a CAR T-cell therapy targeting the BCMA protein — was granted orphan drug status by the U.S.
Gains in 5-Year Survival with Stem Cell Transplant Evident Since Late ’90s
The long-term survival of people with multiple myeloma following autologous stem cell transplant has steadily improved since 1997…
Empliciti Combo Fails to Stem Progression of Newly Diagnosed Multiple Myeloma
Empliciti (elotuzumab), in combination with Revlimid (lenalidomide) and dexamethasone, did not significantly extend the time people with multiple myeloma…
RRMM Trial Testing Safety, Efficacy of TAK-169 Therapy Doses First Patient
The first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of the CD38-targeting therapy TAK-169…
Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000…
Xpovio Combo Significantly Extends Survival in RRMM, Trial Results Show
Adding Xpovio (selinexor) to Velcade (bortezomib) and low-dose dexamethasone significantly extends survival without signs of disease worsening in people with…
Recent Posts
- Treatment before surgery slows PDAC disease progression: Study
- Scientists discover tissue differences in brain cancer in children
- Elahere approved in EU as treatment for ovarian cancer
- Survival better with Blenrep combo than Darzalex for R/R myeloma
- Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL